{
    "clinical_study": {
        "@rank": "95845", 
        "arm_group": [
            {
                "arm_group_label": "DESyne Novolimus Eluting CSS - Arm A", 
                "arm_group_type": "Active Comparator", 
                "description": "Enrollment of up to 50 patients with up to two de novo native coronary artery lesions measuring between 2.5 and 4.0 mm in diameter and </= 34 mm in length receiving the DESyne Novolimus Eluting CSS. (Arm A)"
            }, 
            {
                "arm_group_label": "DESyne BD Novolimus Eluting CSS - Arm B", 
                "arm_group_type": "Active Comparator", 
                "description": "Enrollment of up to 50 patients with up to two de novo native coronary artery lesions measuring between 2.5 and 4.0 mm in diameter and </= 34 mm in length receiving the DESyne BD Novolimus Eluting CSS (Arm B)"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate long-term safety and performance of the DESyne Novolimus Eluting Coronary Stent\n      System and the DESyne BD Novolimus Eluting Coronary Stent System"
        }, 
        "brief_title": "EXCELLA Post-Approval Study", 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "DESyne and DESyne BD are not currently approved for sale in the United States."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The patient must be \u226518 years of age.\n\n          -  The patient must have angina pectoris as defined by the Canadian Cardiovascular\n             Society Classification, documented silent ischemia, or a positive functional study.\n\n          -  The patient has a planned intervention of up to two lesions each coverable by a\n             single stent located in separate major epicardial territories. Each lesion/vessel\n             must meet the following criteria:\n\n          -  De novo lesion\n\n          -  The target lesion reference site must be visually estimated to be \u2265 2.5 mm and \u2264 4.0\n             mm in diameter.\n\n          -  The target vessel must be a major coronary artery or major branch with a visually\n             estimated stenosis of \u2265 50% and <100%.\n\n          -  The visually estimated target lesion length must be \u2264 34 mm (DESyne Novolimus Eluting\n             CSS) (Arm A)*.\n\n          -  The visually estimated target lesion length must be \u2264 34 mm (DESyne BD Novolimus\n             Eluting CSS) (Arm B)*\n\n          -  \u2265 TIMI 1 coronary flow.\n\n             *Subject to commercial availability of product sizes in the specific region/country.\n\n          -  The patient must be an acceptable candidate for coronary artery bypass surgery.\n\n          -  Female subjects of childbearing potential must have a negative pregnancy test within\n             seven (7) days before the procedure and must agree to use a reliable method of\n             contraception from the time of screening through 12 months after the index procedure.\n\n          -  The patient and the patient's physician agree to the follow-up schedule.\n\n          -  The patient or guardian who has been informed of the nature of the study agrees to\n             its provisions and has provided written informed consent, approved by the appropriate\n             Institutional Review Board/Ethical Committee of the respective clinical site.\n\n        Exclusion Criteria:\n\n          -  The patient has a known hypersensitivity or contraindication to aspirin, heparin,\n             ticlopidine, clopidogrel, mTOR inhibitor class drugs, cobalt chromium alloy,\n             methacrylate or polylactide polymer, or sensitivity to contrast which cannot be\n             adequately premedicated.\n\n          -  The patient is a female, intending to get pregnant within the next year.\n\n          -  Target vessel(s) require a staged procedure post index hospitalization discharge\n             through 9 months of this index procedure.\n\n          -  There will be an untreated significant lesion of > 40% diameter stenosis remaining\n             proximal or distal to the target site after the planned intervention.\n\n          -  Previous placement of a stent within 10 mm of the target lesion.\n\n          -  Total occlusion or TIMI 0 coronary flow in the target vessel.\n\n          -  Restenosis lesion\n\n          -  The proximal target vessel or target lesion is severely calcified by visual\n             assessment.\n\n          -  Aorto-ostial location, unprotected left main lesion location, or a lesion within 5 mm\n             of the origin of the LAD or LCX.\n\n          -  Lesion involvement of a significant side branch (branch diameter > 2 mm) that would\n             be covered by stenting.\n\n          -  High probability that treatment other than PTCA or stenting will be required for\n             treatment of the same lesion.\n\n          -  The patient has suffered a myocardial infarction within the past 72 hours and the CK\n             or CK-MB has not returned to normal at the time of the index procedure.\n\n          -  The patient has a history of bleeding diathesis or coagulopathy or will refuse blood\n             transfusions.\n\n          -  The patient suffered a stroke, transient ischemic neurological attack (TIA) or\n             significant gastrointestinal (GI) bleed within the past six months.\n\n          -  The patient has renal insufficiency as determined by a creatinine of > 2.0 mg/dl.\n\n          -  The target lesion, or the target vessel proximal to the target lesion, contains\n             thrombus.\n\n          -  Documented left ventricular ejection fraction of \u2264 25%.\n\n          -  The patient is a recipient of a heart transplant.\n\n          -  The patient has extensive peripheral vascular disease that precludes safe sheath\n             insertion or extreme anti-coagulation.\n\n          -  The patient has other medical illness (i.e., cancer or congestive heart failure) that\n             may cause the patient to be non-compliant with the protocol, confound the data\n             interpretation or is associated withlimited life expectancy (i.e., less than one\n             year).\n\n          -  The patient is simultaneously participating in another investigational device or drug\n             study. Patient must have completed the primary follow-up phase of any previous study.\n             Trials with extended follow-up phases of now commercially available products are not\n             considered investigational studies. Patients may be enrolled one time only in this\n             trial.\n\n          -  Patients who are unable or unwilling to cooperate with study procedures."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02009956", 
            "org_study_id": "ELX-CL-1004"
        }, 
        "intervention": [
            {
                "arm_group_label": "DESyne Novolimus Eluting CSS - Arm A", 
                "intervention_name": "Subjects receiving DESyne Novolimus Eluting CSS - Arm A", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "DESyne BD Novolimus Eluting CSS - Arm B", 
                "intervention_name": "Subjects receiving DESyne BD Novolimus Eluting CSS - Arm B", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 10, 2014", 
        "location": [
            {
                "contact": {
                    "email": "ke.hauptmann@bk-trier.de", 
                    "last_name": "Karl Hauptmann, MD", 
                    "phone": "+49 (651) 208 1780"
                }, 
                "facility": {
                    "address": {
                        "city": "Trier", 
                        "country": "Germany", 
                        "zip": "54292"
                    }, 
                    "name": "Krankenhaus der Barmherzigen Br\u00fcder"
                }, 
                "investigator": {
                    "last_name": "Karl Hauptmann, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "alhaddad63@gmail.com", 
                    "last_name": "Imad Al Haddad, MD", 
                    "phone": "+962 6 5662399"
                }, 
                "facility": {
                    "address": {
                        "city": "Amman", 
                        "country": "Jordan", 
                        "zip": "11152"
                    }, 
                    "name": "Jordan Hospital"
                }, 
                "investigator": {
                    "last_name": "Imad Al Haddad, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Mohammad Jarrah, MD", 
                    "phone": "+962 797 443 688"
                }, 
                "facility": {
                    "address": {
                        "city": "Irbid", 
                        "country": "Jordan", 
                        "zip": "22110"
                    }, 
                    "name": "King Abdullah University Hospital"
                }, 
                "investigator": {
                    "last_name": "Mohammad Jarrah, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ramirotrillo@mac.com", 
                    "last_name": "Ramiro Nouche, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Santiago de Compostela", 
                        "country": "Spain", 
                        "zip": "15706"
                    }, 
                    "name": "Santiago de Compostela University Hospital Complex"
                }, 
                "investigator": {
                    "last_name": "Ramiro Nouche, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "Jordan", 
                "Spain"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "POST MARKETING STUDY OF THE ELIXIR DESyne\u00ae NOVOLIMUS ELUTING CORONARY STENT SYSTEM AND THE DESyne\u00ae BD NOVOLIMUS ELUTING CORONARY STENT SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Jordan: Ethical Committee", 
                "Jordan: Jordanian Food and Drug Administration", 
                "Spain: Ethics Committee", 
                "Germany: Ethics Commission"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Device-oriented Composite Endpoint (DoCE) at 1, 9, 12, and 24 months. DoCE is defined as cardiac death, MI not clearly attributable to a non-intervention vessel, and clinically-indicated target lesion revascularization.", 
            "measure": "Device-oriented Composite Endpoint (DoCE)", 
            "safety_issue": "No", 
            "time_frame": "1, 9, 12, and 24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02009956"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Elixir Medical Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Elixir Medical Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}